Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 63

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 63
---
,381,851          COST OF REVENUE (including $nil and $77,214 of cost of revenue from related parties for the periods ended March 31, 2025 and 2024, respectively)  (1,793,582)  (2,016,820)         GROSS PROFIT  343,493   365,031          OTHER INCOME        Dividend income   8,934   8,946 Interest income  23,568   28,983 Fair value gain on investments in equity securities  4,514   84,785 Gain on disposal of investments in equity securities  -   6,181 Reversal of expected credit losses  25,153   31,752 Others  29,251   41,200 TOTAL OTHER INCOME  91,420   201,847          OPERATING EXPENSES        Sales and marketing    (540,695)  (153,871)Research and development  (12,139)  (11,475)General and administrative (including $1,044 and $nil of rental expenses to related party for the periods ended March 31, 2025 and 2024, respectively)  (391,876)  (315,794)Fair value loss on investments in equity securities  (68,497)  (44,297)Provision for expected credit losses   (40,124)  (120,469)TOTAL OPERATING EXPENSES  (1,053,331)  (645,906)         LOSS FROM OPERATIONS  (618,418)  (79,028)         FINANCE COSTS  (4,909)  (4,661)         LOSS BEFORE TAX  (623,327)  (83,689)         Tax expense  -   (20,068)         NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(623,327) $(103,757)         Other comprehensive income/(loss)        Foreign currency translation gain/(loss)  72,159   (209,908)         COMPREHENSIVE LOSS $(551,168) $(313,665)

 32Table of Contents

Segmented Information